Multi-strain Probiotics to Prevent Necrotizing Enterocolitis in Very Preterm Infants

Condition(s) studied

Investigational drug(s) / intervention(s)

Multi-strain probiotics: Infants will be started on probiotics (Bifidobacterium and Lacticaseibacillus) with enetral feed.

Study summary

The goal of this clinical trial is to evaluate whether multi-strain probiotics of lactobacillus and bifidobacterium can prevent necrotizing enterocolitis (NEC) in preterm infants born at less than 32 weeks of gestation. The main questions it aims to answer are:

* Does the use of a multi-strain probiotic combination reduce the incidence of NEC in preterm infants?
* Are there any adverse effects associated with the administration of this probiotic combination?

Eligibility

Primary outcome measure(s)

• Incidence of necrotizing enterocolitis (NEC — From date of randomization until the date of 34 weeks corrected gestational age or or date of death from any cause, whichever came first
  NEC defined in CNN according to modified Bell's criteria.

Trial sites (4)

More University of Calgary trials in Canada